Farmas USA

XBI ese gap a 58 ...

CNAT

os comente hace un par de meses y la he llevado un tiempo, subiendo en after casi un 200%
Conatus Pharmaceuticals Inc Announces Exclusive Worldwide Option, Collaboration and License Agreement for Emricasan
Novartis a salido con la chequera, es la misma que está en CERU a ver si es la próxima :)

Off-topic

Ando participando en otros hilos de Rankia del Ibex. Y la verdad es que no te das cuenta de lo que hay en este hilo hasta que ves lo de fuera. Que el nivel de aquí es muy alto se sabe pero el nivel de lo de fuera lo hace mucho más alto. Alucino

Más que el nivel, es el ambiente y la generosidad.

El mercado descuenta que se llama "the good life". ;)

Yo estoy invertida en CNAT, ya lo comente por aquí. MIs dos inversiones este año en NASH, que han Sido TBRA y CNAT, han sido dos grandes aciertos
Conatus Pharmaceuticals (CNAT), Novartis (NVS) Enter Collaboration and License Agreement for Emricasan

December 19, 2016 4:32 PM
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan with Novartis. Under the terms of the agreement with Novartis (NYSE: NVS), Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis.

Conatus is eligible to receive significant payments if certain development, regulatory and commercial milestones are met. Furthermore, Conatus is eligible to receive tiered double digit royalties on emricasan single agent sales and tiered single to double digit royalties on sales of combination products containing emricasan. Conatus has the option to co-commercialize emricasan in the United States, including combination therapies, on a cost-sharing and revenue-sharing basis in lieu of U.S. royalties and with reduced ex-U.S. royalties. Conatus retains limited rights to develop other pan-caspase inhibitors.

In addition, Novartis will pay 50% of Conatus’ Phase 2b emricasan development costs after the option exercise, including the planned ENCORE-LF trial in decompensated NASH cirrhosis which, under the current development plan consistent with recent regulatory agency recommendations, will be conducted as Phase 2b rather than Phase 2b/3. Phase 2b emricasan development costs also encompass the ongoing ENCORE-PH trial in primarily compensated NASH cirrhosis, POLT-HCV-SVR trial in post-transplant HCV fibrosis and cirrhosis, and ENCORE-NF trial in NASH fibrosis. Novartis will assume full responsibility for emricasan’s Phase 3 development and all combination product development.

Pues a disfrutarlo, ves mirando barco ;)

Jajaja, veremos.
No escuchaste la última conf call en la que el CEO soltó una carcajada cuando le hablaron del partnering de emericasan? Fue muy reveladora. Debían de andar negociando ya
CNAT